Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss.

What this study adds

Evidence grade: Low

This is a narrative review. This review explains that people with Down syndrome, who have an extra copy of chromosome 21 including the APP gene, develop amyloid plaques early and later develop other Alzheimer's-like brain changes such as tangles, inflammation, and neuron loss. It also notes evidence of compensatory responses that may delay dementia onset, but it does not report a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Head, E., Lott, I. T., Wilcock, D. M., & Lemere, C. A. (2016). Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Current Alzheimer research. https://doi.org/10.2174/1567205012666151020114607

Vancouver

Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Current Alzheimer research. 2016. doi:10.2174/1567205012666151020114607. PMID: 26651341.

BibTeX

@article{head2016-26651341,
  author  = {Head, E. and Lott, I. T. and Wilcock, D. M. and Lemere, C. A.},
  title   = {{Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology}},
  journal = {Current Alzheimer research},
  year    = {2016},
  doi     = {10.2174/1567205012666151020114607},
  pmid    = {26651341},
  url     = {https://doi.org/10.2174/1567205012666151020114607}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review explains that people with Down syndrome, who have an extra copy of chromosome 21 including the APP gene, develop amyloid plaques early and later develop other Alzheimer's-like brain changes such as tangles, inflammation, and neuron loss. It also notes evidence of compensatory responses that may delay dementia onset, but it does not report a treatment or cure.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Current Alzheimer research)
Journal's citation record 1 / 4 Current Alzheimer Research: journal h-index 119 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2016 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 290 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 24.2 citations a year over 12 year(s) since 2016
Impact for its field and year 5 / 6 Cited 31.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 34 other studies in this library
Still being cited 3 / 4 Cited 67 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Cynthia Ann Lemere: h-index 67 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Kentucky: institution h-index 824 (OpenAlex)
Multicenter collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 26651341)
Free to read 0 / 2 Behind a paywall — scores zero
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.

Later studies that cite this one

33 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Inflammation and the immune system from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →